Top Page
Roquefort Investments PLC
(LSE:ROQ)
Roquefort Investments PLC (ROQ) vs. iShares MSCI United Kingdom ETF (EWC)
Roquefort Investments PLC Business Overview & Revenue Model
Roquefort Investments PLC Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 200.00K | 0.00 | 719.00 |
| Gross Profit | -2.70K | -16.00K | 200.00K | 0.00 | -9.35K |
| EBITDA | -926.73K | -1.11M | -1.93M | 0.00 | -352.40K |
| Net Income | -882.45K | -971.80K | -1.74M | -1.62M | -917.43K |
Balance Sheet | |||||
| Total Assets | 5.66M | 5.75M | 6.09M | 7.77M | 4.56M |
| Cash, Cash Equivalents and Short-Term Investments | 182.92K | 337.11K | 537.32K | 2.32M | 899.72K |
| Total Debt | 383.65K | 400.09K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 909.12K | 861.73K | 589.02K | 561.58K | 477.43K |
| Stockholders Equity | 4.75M | 4.89M | 5.50M | 7.21M | 4.08M |
Cash Flow | |||||
| Free Cash Flow | -645.62K | -783.73K | -1.79M | -1.58M | -2.62M |
| Operating Cash Flow | -588.75K | -783.73K | -1.73M | -1.58M | -2.62M |
| Investing Cash Flow | -57.06K | 0.00 | -52.57K | -103.48K | -1.11M |
| Financing Cash Flow | 236.00K | 584.91K | -58.00 | 3.10M | 4.63M |
Roquefort Investments PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | £314.67M | 9.45 | 15.04% | ― | 1231.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £27.61M | -5.79 | -202.14% | ― | ― | 23.76% | |
44 Neutral | £1.88M | -1.80 | -18.71% | ― | ― | ― | |
44 Neutral | £15.06M | -9.38 | -164.37% | ― | -11.43% | 23.40% | |
43 Neutral | £5.75M | -5.18 | -433.59% | ― | ― | ― | |
42 Neutral | £229.72M | ― | ― | ― | ― | ― |
Roquefort Investments PLC Corporate Events
Roquefort Therapeutics has announced that its broker, SP Angel Corporate Finance, has published a new research note analysing the company’s proposed transaction with clinical-stage oncology firm Coiled Therapeutics and AI-driven drug discovery specialist A2A Pharmaceuticals. The note, now available via Roquefort’s website, is expected to give investors further insight into the strategic rationale for the deal, which links Roquefort to Coiled’s brain-penetrant cancer candidate AO-252 already in Phase I trials, and to A2A’s generative AI-enabled SCULPT platform and proven spin-out model, potentially strengthening Roquefort’s position in oncology drug development and long-term value creation.
The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.
Roquefort Therapeutics PLC announced an amendment to its exclusive license agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. for the AO-252 drug, extending the long stop date to March 16, 2026. The amendment reflects significant progress in the Phase I clinical trial, which has expanded to include all solid tumors and prioritized prostate cancer. This strategic focus is supported by promising pre-clinical data and positive feedback from potential partners, highlighting the commercial interest in novel oral therapies for prostate cancer. The extension allows more time for data readouts and involves changes to the commercial terms, including an increase in consideration shares, underscoring the potential value of the AO-252 program.
Roquefort Therapeutics has announced the conversion of £80,000 worth of convertible loan notes into 6,282,264 new ordinary shares. This conversion, which includes accrued interest, is part of the company’s financial strategy to manage its capital structure. The new shares will be admitted to trading on the London Stock Exchange, increasing the company’s total issued share capital to 163,726,294 ordinary shares. This move is significant for shareholders as it affects voting rights and shareholding calculations under regulatory rules.
Roquefort Therapeutics announced that its ordinary shares will be marked ex-entitlement for Unlisted Redeemable Non-Voting Shares as of December 1, 2025. Shareholders and convertible loan note holders registered by November 28, 2025, are eligible to receive these shares, with further details on the entitlement ratio and issuance to be announced later.
Roquefort Therapeutics has announced the determination of the record date for entitlement to new unlisted redeemable non-voting shares, linked to its Midkine Investments portfolio. Shareholders and convertible loan note holders as of November 30, 2025, will be eligible for these shares, which aim to facilitate future distribution of Midkine Investments shares, enhancing shareholder value.
Roquefort Therapeutics PLC announced that Dr. Darrin Disley, the Interim Managing Director, has purchased 5,000,000 ordinary shares of the company at an average price of 1.70 pence per share, amounting to a total consideration of £85,000. This acquisition increases Dr. Disley’s total shareholding to 7,024,196 shares, representing 4.46% of the company’s issued capital. This move could signal confidence in the company’s strategic direction and its ongoing efforts to acquire rights to a novel cancer treatment drug, potentially impacting its market positioning and stakeholder interests.
Roquefort Therapeutics PLC has entered into a binding exclusive license agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. for the worldwide rights to AO-252, a first-in-class drug targeting TACC3 protein in multiple cancers. The agreement involves a reverse takeover and a proposed name change to Coiled Therapeutics PLC. The transaction includes an equity placing to raise funds for clinical trials and operational expansion. This strategic move aims to enhance Roquefort’s market position by advancing AO-252 through clinical stages, potentially benefiting up to 350,000 patients in the US and Europe, and achieving significant value milestones.
Roquefort Therapeutics PLC has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd, potentially earning up to $25 million in milestone payments and a royalty on sales. This strategic move is part of a broader group restructuring, which includes the sale of its subsidiary Lyramid Pty Ltd to Pleiades, contingent on successful fundraising. The restructuring aims to benefit existing shareholders and allow Roquefort to focus on a transformative acquisition with A2A Pharmaceuticals and Coiled Therapeutics, enhancing its position in the biotech industry.